Cochrane · systematic review · CD001423
Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement
Franco, JVA, Trivisonno, L, Sgarbossa, NJ, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 16.7%Low 2 · 33.3%Moderate 1 · 16.7%High 2 · 33.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySerenoa repens compared to placebo or no intervention
Population: lower urinary tract symptoms due to benign prostatic hyperplasia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Urologic symptom scoreMeasured by IPSS scores (range 0 to 35)Higher scores indicate worse symptoms. Serenoa repens vs placebo or no intervention | no estimate extracted | 9 studies · 1681 participants | High |
Quality of lifeMeasured by IPSS‐QoL score (range 0 to 6) Serenoa repens vs placebo or no intervention | no estimate extracted | 5 studies · 1001 participants | High |
Adverse eventsCumulative incidence Serenoa repens vs placebo or no intervention | RR 1.01 [0.77, 1.31] | 12 studies · 2399 participants | Moderate Downgraded: risk of bias, imprecision |
Serenoa repens in combination with other phytotherapy versus placebo or no intervention
Population: lower urinary tract symptoms due to benign prostatic hyperplasia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Urologic symptom scoreMeasured by IPSS scores (range 0 to 35)Higher scores indicate worse symptoms. Serenoa repens in combination with other phytotherapy vs placebo or no intervention | no estimate extracted | 4 studies · 460 participants | Low Downgraded: imprecision, inconsistency |
Quality of lifeMeasured by IPSS‐QoL score (range 0 to 6) Serenoa repens in combination with other phytotherapy vs placebo or no intervention | no estimate extracted | 2 studies · 265 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse eventsCumulative incidence Serenoa repens in combination with other phytotherapy vs placebo or no intervention | RR 0.91 [0.58, 1.41] | 4 studies · 481 participants | Low Downgraded: imprecision |
SR compared to placebo for benign prostatic hyperplasia
Population: men with benign prostatic hyperplasia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
AUA total score, mean change from baseline American Urological Association Symptom Score. Scale from: 0 to 35. SR vs placebo | no estimate extracted | 2 studies · 582 participants | High |
Peak urine flow, mean change from baseline millilitres/second SR vs placebo | no estimate extracted | 3 studies · 667 participants | High |
Clinical responders ≥ 3 point improvement in AUA SR vs placebo | RR 0.96 [0.76, 1.22] | 1 study · 357 participants | High |
SR compared to placebo for benign prostatic hyperplasia
Population: men with benign prostatic hyperplasia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
AUA total score, mean change from baseline American Urological Association Symptom Score. Scale from: 0 to 35. SR vs placebo | no estimate extracted | 2 studies · 582 participants | High |
Peak urine flow, mean change from baseline millilitres/second SR vs placebo | no estimate extracted | 3 studies · 667 participants | High |
Clinical responders ≥ 3 point improvement in AUA SR vs placebo | RR 0.96 [0.76, 1.22] | 1 study · 357 participants | High |